0001225208-24-007395.txt : 20240710
0001225208-24-007395.hdr.sgml : 20240710
20240710173643
ACCESSION NUMBER: 0001225208-24-007395
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240710
FILED AS OF DATE: 20240710
DATE AS OF CHANGE: 20240710
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BOBO DONALD E JR
CENTRAL INDEX KEY: 0001196661
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15525
FILM NUMBER: 241110672
MAIL ADDRESS:
STREET 1: C/O EDWARDS LIFESCIENCES
STREET 2: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edwards Lifesciences Corp
CENTRAL INDEX KEY: 0001099800
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 364316614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
BUSINESS PHONE: 9492502500
MAIL ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP.
DATE OF NAME CHANGE: 20090225
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP
DATE OF NAME CHANGE: 20000203
FORMER COMPANY:
FORMER CONFORMED NAME: CVG CONTROLLED INC
DATE OF NAME CHANGE: 19991126
4
1
doc4.xml
X0508
4
2024-07-10
0001099800
Edwards Lifesciences Corp
EW
0001196661
BOBO DONALD E JR
ONE EDWARDS WAY
IRVINE
CA
92614
1
CVP,Strategy/Corp Development
1
Common Stock
2024-07-10
4
M
0
5000.0000
45.2767
A
51935.7184
D
Common Stock
2024-07-10
4
S
0
5000.0000
93.2948
D
46935.7184
D
Common Stock
38615.0363
I
401(k)
Common Stock
135152.0000
I
By Trust
Employee Stock Option (Right to Acquire)
45.2767
2024-07-10
4
M
0
5000.0000
0.0000
D
2018-06-17
2025-05-16
Common Stock
5000.0000
55500.0000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.
This transaction was executed in multiple trades at prices ranging from $92.910 to $93.655. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact
2024-07-10